Syndax announces revumenib abstracts to be presented at the 66th ash annual meeting

– new monotherapy and combination data in acute leukemia further highlight revumenib's compelling clinical profile –  – 64% orr (62/97) in expanded dataset of patients with r/r kmt2ar acute leukemia in ph 2 augment-101 pivotal cohort – –  88% orr (23/26) in save trial testing revumenib, venetoclax and decitabine/cedazuridine combination in r/r aml – waltham, mass. , nov. 5, 2024 /prnewswire/ -- syndax pharmaceuticals (nasdaq:sndx) today announced that multiple abstracts evaluating revumenib, an oral small molecule menin inhibitor, have been accepted for oral presentation at the 66th american society of hematology (ash) annual meeting being held in san diego, california, december 7-10, 2024.
ASH Ratings Summary
ASH Quant Ranking